Day One Biopharmaceuticals Reports Strong Revenue Growth and Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2024
0mins
Should l Buy DAWN?
Source: Business Insider
Day One Biopharmaceuticals Inc shares surged by 25.62% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.
The company reported a preliminary net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, driven by strong demand for its treatment OJEMDA™ for pediatric low-grade glioma. Additionally, the acquisition of Mersana for $25 per share is expected to enhance Day One's oncology pipeline, particularly with the innovative Emi-Le program targeting rare cancers, further solidifying its market position.
This impressive revenue growth and strategic acquisition position Day One favorably for future expansion, with projected revenues for 2026 expected to reach between $225 million and $250 million, indicating a strong commitment to developing new therapies and addressing unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DAWN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DAWN
Wall Street analysts forecast DAWN stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.440
Low
16.00
Averages
22.29
High
29.00
Current: 21.440
Low
16.00
Averages
22.29
High
29.00
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings Corporation, Day One Biopharmaceuticals, and Veris Residential for potential violations of federal securities laws and fiduciary duties to shareholders, with transaction prices at $16.50, $21.50, and $19.00 per share, respectively, which may impact shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to handle matters on a no-cost basis, aiming to secure increased consideration and additional disclosures for shareholders, thereby protecting investor interests.
- Legal Service Model: Halper Sadeh LLC operates on a contingent fee basis, meaning shareholders do not incur legal fees unless the case is successful, which reduces financial risk for shareholders and enhances their willingness to engage in legal action.
- Global Investor Support: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors in the past, demonstrating its expertise and influence in safeguarding investor rights.
See More
M&A Deal Closures Present Opportunities: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies being acquired are expected to rise upon the completion of these deals.
See More
Opportunities Arise from Finalizing M&A Deals: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies involved in these acquisitions are expected to rise once the deals are finalized.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) regarding its sale to Servier for $21.50 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The firm is also scrutinizing Talkspace, Inc. (NASDAQ:TALK) in its sale to Universal Health Services, Inc. for $5.25 per share, urging shareholders to understand their rights and options to safeguard their interests.
- UniFirst Transaction Review: The sale of UniFirst Corporation (NYSE:UNF) to Cintas Corporation, offering $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased compensation and disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for victims in the past, highlighting its crucial role in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings Corporation, Day One Biopharmaceuticals, and Veris Residential for potential violations of federal securities laws and fiduciary duties to shareholders, with transaction prices at $16.50, $21.50, and $19.00 per share, respectively, which may impact shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to handle matters on a no-cost basis, aiming to secure increased consideration and additional disclosures for shareholders, thereby protecting investor interests.
- Legal Service Model: Halper Sadeh LLC operates on a contingent fee basis, meaning shareholders do not incur legal fees unless the case is successful, which reduces financial risk for shareholders and enhances their willingness to engage in legal action.
- Global Investor Support: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors in the past, demonstrating its expertise and influence in safeguarding investor rights.
See More
M&A Deal Closures Present Opportunities: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies being acquired are expected to rise upon the completion of these deals.
See More
Opportunities Arise from Finalizing M&A Deals: Target Janus Henderson and Other Stocks.
- Merger and Acquisition Activity: The year has seen significant merger and acquisition activity, with many deals nearing closure.
- Stock Performance: Stocks of companies involved in these acquisitions are expected to rise once the deals are finalized.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) regarding its sale to Servier for $21.50 per share in cash, potentially infringing on shareholder rights, aiming to ensure fair treatment for investors.
- Shareholder Rights Protection: The firm is also scrutinizing Talkspace, Inc. (NASDAQ:TALK) in its sale to Universal Health Services, Inc. for $5.25 per share, urging shareholders to understand their rights and options to safeguard their interests.
- UniFirst Transaction Review: The sale of UniFirst Corporation (NYSE:UNF) to Cintas Corporation, offering $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased compensation and disclosures for shareholders to ensure transaction transparency.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for victims in the past, highlighting its crucial role in protecting investor rights.
See More
